ADAM12 and colorectal adenocarcinoma: Similarly, ADAM12 appeared to have prognostic value for disease-specific survival (DSS) in the “colorectal adenocarcinoma TCGA PanCancer Atlas” dataset; at month 75, the proportion of DSS events was 16% (shorter DSS) in the high-ADAM12-expression group (z-score > 0.3), compared to 11% (longer DSS) in the low-expression group (z-score < 0.03; Figure 2B, p = 0.05, HR = 1.61).